A blood-sugar measure fell 16 and 20 mmol/mol with 30 mg and 60 mg daily, versus 4 mmol/mol with placebo over 16 weeks.A blood-sugar measure fell 16 and 20 mmol/mol with 30 mg and 60 mg daily, versus 4 mmol/mol with placebo over 16 weeks.
Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.